Hester Biosciences Ltd
Hester Biosciences Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
FY'25 focused on improving operational efficiency and strengthening profitability, setting a solid foundation for future growth. Hester Biosciences aims to strengthen profitability through continued operational improvements and cost management.
From Hester Biosciences Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY'25 focused on improving operational efficiency and strengthening profitability, setting a solid foundation for future growth.
- Divisional product sales grew 13% despite market headwinds; poultry vaccines and therapeutic products showing steady demand.
- Expansion in Africa and parts of the Middle East and Central Asia is a key growth focus, with emphasis on building market presence.
- Launch of Avian Influenza vaccine expected in FY'26 to be a significant growth driver.
- Growth in Animal Health and Pet Care segments aimed to reduce dependence on poultry vaccines; health product segment is about 10 years old and expected to grow steadily.
- Capacity expansion coming online by Q2-Q3 FY'26, with gradual utilization increase over three years.
- Africa operations expected to breakeven in 1-2 years, with growing order pipeline and regional presence.
- Focus on expanding preventive care, biosecurity products, and proprietary formulations to broaden market reach and sustainability.
Profitability & Margins
See what Hester Biosciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current CAPEX plans are limited, primarily focused on maintenance.
- The fill-finish facility is expected to be commercially utilized by Q2 or latest Q3 of FY'26.
- The BSL-3 facility is awaiting administrative approval from BIRAC; commercialization timeline remains uncertain.
- No concrete new CAPEX plans have been finalized at this time.
- Strategic focus is on operational efficiency, strengthening profitability, and expanding international presence, especially in Africa and Asia.
- Investment in distribution network expansion, including appointing marketing managers in African countries, is ongoing.
- The new capacity (Rs. 176 crore capital work in progress) is being gradually utilized; expected to reach good production levels in about 3 years.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hester Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Hester Biosciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹100 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hester Biosciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Biocon Ltd (Q4 FY25)
FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page…
- Natural Capsules (Q4 FY25)
196 crore, implying about Rs. Key concall takeaways from Natural Capsules Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Laurus Labs Ltd (Q4 FY25)
Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. Key concall takeaways from Laurus Labs…
- Wockhardt Ltd (Q4 FY25)
EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. Key concall takeaways from Wockhardt…
Frequently Asked Questions
What were Hester Biosciences Ltd Q4 FY25 results?
FY'25 focused on improving operational efficiency and strengthening profitability, setting a solid foundation for future growth. Hester Biosciences aims to strengthen profitability through continued operational improvements and cost management.
What is Hester Biosciences Ltd share price analysis?
Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.7 with a market cap of ₹2,054 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hester Biosciences Ltd planning capital expenditure?
Current CAPEX plans are limited, primarily focused on maintenance. - The fill-finish facility is expected to be commercially utilized by Q2 or latest Q3 of FY'26. - The BSL-3 facility is awaiting administrative approval from BIRAC; commercialization timeline remains uncertain. - No concrete new CAPEX plans have been finalized at this time. - Strategic focus is on operational efficiency, strengthening profitability, and expanding international presence, especially in Africa and Asia. - Investment in distribution network expansion, including appointing marketing managers in African countries, is ongoing. - The new capacity (Rs.
Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.